Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma

BACKGROUND AND AIM: Molecular‐targeted therapies such as sorafenib and lenvatinib have long been used as first‐line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known as post‐p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Yoshihiko, Yamamoto, Atsushi, Minami, Akihiro, Momose, Kenji, Mimura, Takuya, Kim, Soo Ki, Hayashi, Hiroki, Kado, Takuo, Hirano, Hirotaka, Hirohata, Seiya, Yoon, Seitetsu, Nishi, Katsuhisa, Tei, Hiroshi, Tanaka, Hidenori, Oouchi, Sachiko, Matsuura, Takanori, Yasutomi, Eiichiro, Hatazawa, Yuri, Shiomi, Yuuki, Ueda, Yoshihide, Kodama, Yuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218537/
https://www.ncbi.nlm.nih.gov/pubmed/35774348
http://dx.doi.org/10.1002/jgh3.12772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218537/
https://www.ncbi.nlm.nih.gov/pubmed/35774348
http://dx.doi.org/10.1002/jgh3.12772

Ejemplares similares